Background: Lipoteichoic Acid (LTA) of Lactic Acid Bacteria (LAB) is a cell wall component of LAB with immunomodulatory properties towards inflammatory skin diseases due to immune dysregulation, such as atopic dermatitis. Topical glucocorticoids are given as the mainstay therapy in some inflammatory skin diseases. However, the adverse effects of topical glucocorticoids are commonly found, such as skin atrophy, reduced pigmentation, and masking-effect of skin infections. Therefore, safer therapy for inflammatory skin diseases is necessary to be developed. This study aimed to analyze the potential of LTA of LAB against glucocorticoid receptors (GR) as a topical therapy for inflammatory skin diseases. Methods: This study used the bioinformatics method with molecular docking to predict the binding site and the binding affinity of LTA of LAB to GR and analyze the toxicity of LTA of LAB. According to the previous studies, this research was also conducted within silico/ molecular docking. Data were analyzed using Toxtree v 2. 6.13 application to evaluate the skin irritation. Results: LAB’s lipoteichoic acid (LTA) has the same binding site with glucocorticoid control compounds to the GR. Toxicity analysis shows that LTA of LAB is not irritative to the skin. Conclusion: LAB’s lipoteichoic acid (LTA) is potential as alternative topical therapy for inflammatory skin diseases.
- glucocorticoid receptors
- inflammatory skin diseases
- Lipoteichoic acid of lactic acid bacteria